Hepatitis Clinical Trials

Showing 1801-1820 of 2,113 trials

PEG-IFN in HBV Patients With Incomplete Response to NA

NCT00883844

Treatment with a nucleoside analogue and subsequent viral decline has shown to partially restore immune hyporesponsiveness in chronic hepatitis B patients. Recent pilot studies investigating whether the effect of lowering viral load with nucleoside analogue therapy prior to the initiation of peginterferon results in higher sustained off-treatment responses showed contradictory findings. The aim of this study is to investigate sustained off-treatment response to peginterferon alfa-2b in chronic HBeAg-positive hepatitis B patients who are pretreated with nucleos(t)ide analogues, thereby lowering viral load

Chronic Hepatitis B

Foundation for Liver Research11 participantsStarted Apr 2009

Amsterdam, Netherlands • Rotterdam, Netherlands

COMPLETEDNA

Genetic Polymorphisms of Interleukin-1B and TNF-A and HBV-Related Hepatocellular Carcinoma

NCT00629486

By detecting polymorphisms of IL-1β and TNF-α,this study aims to find the effects of cytokine gene polymorphisms(and their interaction) on susceptibility and severity of HBV-related HCC.

Hepatitis BHepatocellular CarcinomaChronic Liver Disease

Kaohsiung Medical University Chung-Ho Memorial Hospital300 participantsStarted Jan 2007

Kaohsiung City, Kaohsiung, Taiwan • Kaohsiung City, Kaohsiung, Taiwan

COMPLETEDPhase 1

TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

NCT00741169

The purpose of this study is to assess the interactions seen when somebody doses with TMC435350 and Rifampin (commercial form of antibiotic).

Hepatitis CHCVTuberculosis+2 more

Tibotec Pharmaceuticals, Ireland21 participantsStarted Jun 2008

PEG-IFN in HBV Patients With Incomplete Response to NA

Genetic Polymorphisms of Interleukin-1B and TNF-A and HBV-Related Hepatocellular Carcinoma

TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

Related Searches

A Network & Dyad HIV Prevention Intervention for IDU's - 1

Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients

Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT

Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis

Treatment of Alcohol-Related Hepatitis With Arginine

TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients

Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial

Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants

A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382

The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis

Acceptability of Hepatitis B Vaccination in General Practitioners and Paediatricians

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C

Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Acceptability of Hepatitis B Vaccination in General Population

HIV and Hepatitis Care Coordination in Methadone Treatment

Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C

Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)